Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Financing Strategies of Influenza Vaccination in China

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04038333
Recruitment Status : Recruiting
First Posted : July 30, 2019
Last Update Posted : March 16, 2020
Sponsor:
Collaborators:
Centers for Disease Control and Prevention, China
Fudan University
Shandong University
Information provided by (Responsible Party):
Hai Fang, Peking University

Brief Summary:
This trial focuses on influenza vaccination among three recommended groups in China. Data concerning the economic burden of influenza-like illness (ILI), vaccine hesitancy, discrete choice experiment and willingness to pay for vaccines will be collected via questionnaires, and the financing strategies of influenza vaccines in China will be further analyzed. Besides, the knowledge, attitude/belief and practice (KAP) of medical staff will also be asked in a supplementary questionnaire.

Condition or disease Intervention/treatment
Influenza Vaccines Influenza, Human Cost of Illness Health Knowledge, Attitudes, Practice Immunization Programs Other: No intervention

Detailed Description:

This trial focuses on influenza vaccination among three recommended groups in China, including children (aged between 6 to 59 months), the elderly (aged 60 years old or above), and adult patients with chronic diseases (aged below 60 years old).

The questionnaires will collect data on the economic burden of influenza-like illness (ILI), vaccine hesitancy, discrete choice experiment and willingness to pay for vaccines, and the financing strategies of influenza vaccines in China will be further analyzed accordingly.

Besides the three recommended groups, vaccination and health care personnel will also be asked about their knowledge, attitude/belief and practice (KAP) in a supplementary questionnaire.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 13542 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Influenza Vaccination Among Three Recommended Groups in China: Economic Burden, Vaccine Hesitancy, Discrete Choice Experiment, Willingness to Pay and Financing Strategies
Actual Study Start Date : August 1, 2019
Actual Primary Completion Date : October 30, 2019
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Group/Cohort Intervention/treatment
Children
Interviewees are parents or grandparents of children aged between 6 to 59 months.
Other: No intervention
This is an observational study without any interventions.

Elderly
Interviewees are the elderly aged 60 years old or above.
Other: No intervention
This is an observational study without any interventions.

Chronic disease patients
Interviewees are adult patients with chronic diseases aged below 60 years old.
Other: No intervention
This is an observational study without any interventions.

Vaccination and health care personnel
Interviewees are vaccination and health care personnel in each study site.
Other: No intervention
This is an observational study without any interventions.




Primary Outcome Measures :
  1. economic burden of influenza-like illness (ILI) [ Time Frame: 2019.08-2019.09 ]
    Questions were designed in the questionnaire to ask the economic burden of influenza-like illness (ILI), including direct and indirect costs. Specifically, direct costs include inpatient cost (both out-of-pocket and reimbursed, range 0-100,000), hospitalization cost (both out-of-pocket and reimbursed, range 0-500,000), drug cost (both out-of-pocket and reimbursed, range 0-100,000), transportation cost (range 0-100,000), accommodation cost range (0-100,000) and food cost (range 0-100,000). Indirect cost include missed working days of the patients and their relatives/friends.

  2. willingness to pay [ Time Frame: 2019.08-2019.09 ]
    Questions were designed in the questionnaire to ask interviewees' willingness to pay for influenza vaccination. A value between 0 and 150 RMB will be randomly generated, and ask the respondent whether he or she is willing to pay for influenza vaccination. For example, one is asked "Would you like pay 102 for influenza vaccination?" If the answer is "Yes", then he or she will be asked "Would you like pay 112 for influenza vaccination?" If the answer is "No", then he or she will be asked "Would you like pay 92 for influenza vaccination?" The willingness to pay is then settled and recorded. Moreover, the proportion of vaccination cost paid by individuals will be asked (if others will be paid by health insurance and the government).


Secondary Outcome Measures :
  1. vaccine hesitancy [ Time Frame: 2019.08-2019.09 ]
    Questions were designed in the questionnaire to evaluate the degree of vaccine hesitancy of interviewees. Respondents will be asked abound their confidence, convenience and complacency about vaccination of different vaccines (include influenza, Hib, PCV, Rota and chickenpox), so as to further explore the influencing factors of people's vaccination behaviors.

  2. financing strategies [ Time Frame: 2019.08-2019.09 ]

    Financing strategies will be further discussed according to literature review, government reports, and the results of willingness to pay.

    Literature review will be done to learn about the financing strategies of influenza vaccination all over the world. Government reports on basic public health financing will be an important evidence and reference. The results of willingness to pay from the questionnaire estimate the amount (0-150) and proportion (0-100%) an individual is willing to pay for influenza vaccination.

    Combining the three information sources, a supply-demand curve can be drawn to decide the optimal financing strategies of influenza vaccine, and the cross-region inequities in China will also be taken into consideration.


  3. discrete choice experiment [ Time Frame: 2019.08-2019.09 ]
    An extra questionnaire was specially designed for a small portion of randomly chosen interviewees to conduce discrete choice experiment. In the discrete choice experiment, different packages of vaccine will be given for respondents to choose from. These packages have different characteristics in terms of protection duration, vaccine cost, efficacy, safety and production place. In the experiment, participants are asked to choose one package from 10 pairs of packages (package A and package B) according to their own preferences. Their preferences (protection duration, vaccine cost, efficacy, safety and production place) will be calculated and ranked according to the experiment results.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Three recommended groups for influenza vaccination in China, including children (aged between 6 to 59 months), the elderly (aged 60 years old or above), and adult patients with chronic diseases (aged below 60 years old); Vaccination and health care personnel in each study site.
Criteria

Inclusion Criteria:

  • (For children group) children aged between 6 to 59 months.
  • (For the elderly group) the elderly aged 60 years old or above.
  • (For chronic disease patient group) adult patients with chronic diseases aged below 60 years old.
  • (For medical staff) general practitioners and vaccination staff.
  • Interviewees with informed consent.

Exclusion Criteria:

  • Those cannot be surveyed for physical reasons.
  • Those with communication barriers.
  • Those who do not agree to participate in the survey.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04038333


Contacts
Layout table for location contacts
Contact: Xiaozhen Lai, Bachelor 18811731336 laixiaozhen@pku.edu.cn

Locations
Layout table for location information
China, Beijing
Peking University Health Science Center Recruiting
Beijing, Beijing, China, 100191
Contact: Fang Hai, PhD       hfang@hsc.pku.edu.cn   
China, Shandong
Shandong University Recruiting
Jinan, Shandong, China
Contact: Shunping Li         
China, Shanghai
Fudan University Recruiting
Shanghai, Shanghai, China
Contact: Zhiyuan Hou, PhD         
Sponsors and Collaborators
Peking University
Centers for Disease Control and Prevention, China
Fudan University
Shandong University
Investigators
Layout table for investigator information
Principal Investigator: Hai Fang, PhD Peking University
Publications of Results:

Layout table for additonal information
Responsible Party: Hai Fang, Professor, Peking University
ClinicalTrials.gov Identifier: NCT04038333    
Other Study ID Numbers: IRB00001052-19076
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: March 16, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: It is not yet known if there will be a plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases